In the second quarter of 2025, Mayo Clinic Laboratories expanded its test catalog with several innovative new tests.

The laboratory test catalog is no longer just a reference list — it’s a strategic asset. By expanding its content, laboratories can improve satisfaction and experience.

After mysterious neurological symptoms began in 2010, Brad Karon, M.D., Ph.D., was diagnosed with paraneoplastic syndrome, a rare condition that led to groundbreaking research and test development at Mayo Clinic. Years later, pulmonary fibrosis and a double lung transplant would test him once again — and redefine his resilience.

A specific type of fungal species, Candida auris, is raising concern in health care facilities around the world. First discovered in Japan in 2009, Candida auris is responsible for an increasing number of serious and often fatal fungal infections. Nancy Wengenack, Ph.D., director of the Mycology and Mycobacteriology Laboratories at Mayo Clinic Laboratories, explains why these infections are difficult to treat.

Rachel is a referral specialist serving as the important link between Mayo Clinic Laboratories and our clients. With an eye on quality assurance, she helps patients and clinicians get answers faster.

Sean Pittock, M.D., explains how Mayo Clinic Laboratories' novel Ma2 test aids diagnosis of autoimmune neurology disorders that are often caused by underlying cancer. Rapid diagnosis is key to preventing significant disability and disease.

This week's Research Roundup feature: Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis.

While the accelerated innovation and increased access to testing that’s occurred because of the COVID-19 pandemic has been critically important to worldwide health care, so too has the crash course in laboratory testing and pathology the general public has received throughout the entirety of the pandemic.

Thank you to all laboratory professionals for their efforts to provide critical answers for patients every day, and drive innovation in the field of medicine.

Top highlights include: Millions expected to lose dental care coverage, overdose deaths of elderly on the rise, and Minnesota Health Department urges caution for well owners as flood waters rise.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Emily Shaffer, D.O., a resident physician in pathology and laboratory medicine for Northwell Health in Roslyn, New York, to talk about her experience participating on a laboratory inspection team.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Nancy Wengenack, Ph.D., director of the Mycology and Mycobacteriology Laboratories at Mayo Clinic, discuss the increased focus on fungi and why emerging fungal infections can be concerning for health care facilities.

Almost four years ago, Mayo Clinic launched the Digital Pathology Program, a major pathology initiative. Phase 2 of this multi-phase rollout has recently been completed, which involved the implementation of cutting-edge digital equipment and software, and converting glass slides of patient samples into digital images. The conversion enables pathologists and laboratory technologists to view, store, retrieve, and share medical images more universally, without waiting for glass slides to be retrieved and delivered. This has significantly improved patient care because pathologists can now discuss cases with clinicians and surgeons in real time.

This week's Research Roundup feature: Renal involvement in systemic sclerosis.

Matthew Binnicker, Ph.D., director of Mayo Clinic’s Clinical Virology Laboratory, provides insight on the newest COVID-19 subvariant – XBB.1.16, also known as “Arcturus.”